UA120927C2 - Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл - Google Patents

Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл

Info

Publication number
UA120927C2
UA120927C2 UAA201609970A UAA201609970A UA120927C2 UA 120927 C2 UA120927 C2 UA 120927C2 UA A201609970 A UAA201609970 A UA A201609970A UA A201609970 A UAA201609970 A UA A201609970A UA 120927 C2 UA120927 C2 UA 120927C2
Authority
UA
Ukraine
Prior art keywords
triterpenoids
substituted
aromatic ring
inhibitory activity
hiv maturation
Prior art date
Application number
UAA201609970A
Other languages
English (en)
Inventor
Сін-Юень Сіт
Син-Юень Сит
Янь ЧЕНЬ
Цзе ЧЕНЬ
Джейкоб Свідорскі
Джейкоб Свидорски
Брайан Лі Венейблз
Брайан Ли Венэйблз
Нюй Сінь
Нюй Синь
Ніколас А. Мінвелл
Николас А. Минвелл
Аліша Реґейро-Рен
Алиша Регейро-Рен
Річард А. Гарц
Ричард А. Гарц
Лі Сюй
Ли Сюй
Чжен ЛЮ
Original Assignee
Віів Гелскер Юк (Но.4) Лімітед
Виив Гелскер Юк (Но.4) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53002809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA120927(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Віів Гелскер Юк (Но.4) Лімітед, Виив Гелскер Юк (Но.4) Лимитед filed Critical Віів Гелскер Юк (Но.4) Лімітед
Publication of UA120927C2 publication Critical patent/UA120927C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Представленими є сполуки, які мають лікувальні та біоактивні властивості, їх фармацевтичні композиції та способи застосування. Зокрема, представленими є тритерпеноїди, які мають унікальну противірусну дію як інгібітори дозрівання ВІЛ, а саме сполуки формули І: , Формула I де X є вибраним з С4-8циклоалкілу, С4-8циклоалкенілу, С4-9спіроциклоалкілу, С4-9спіроциклоалкенілу, С4-8оксациклоалкілу, С4-8діоксациклоалкілу, С6-8оксациклоалкенілу, С6-8діоксациклоалкенілу, С6циклодіалкенілу, С6оксациклодіалкенілу, С6-9оксаспіроциклоалкілу та С6-9оксаспіроциклоалкенілового кільця, такі, де X є заміщеним А, де А є С1-6галогеналкілом. Згадані сполуки є корисними в лікуванні ВІЛ та СНІД.
UAA201609970A 2014-04-11 2015-04-09 Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл UA120927C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461978306P 2014-04-11 2014-04-11
PCT/US2015/025029 WO2015157483A1 (en) 2014-04-11 2015-04-09 Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent

Publications (1)

Publication Number Publication Date
UA120927C2 true UA120927C2 (uk) 2020-03-10

Family

ID=53002809

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201609970A UA120927C2 (uk) 2014-04-11 2015-04-09 Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл

Country Status (35)

Country Link
US (5) US9527882B2 (uk)
EP (2) EP3129392B1 (uk)
JP (1) JP6568202B2 (uk)
KR (1) KR102411082B1 (uk)
CN (1) CN106604909B (uk)
AR (1) AR101077A1 (uk)
AU (1) AU2015243500B2 (uk)
BR (1) BR112016023414B1 (uk)
CA (1) CA2944778C (uk)
CL (1) CL2016002528A1 (uk)
CR (1) CR20160472A (uk)
CY (1) CY1123742T1 (uk)
DK (1) DK3129392T3 (uk)
DO (1) DOP2016000277A (uk)
EA (1) EA030178B1 (uk)
ES (1) ES2828705T3 (uk)
HR (1) HRP20201645T1 (uk)
HU (1) HUE051719T2 (uk)
IL (1) IL248053B (uk)
LT (1) LT3129392T (uk)
MA (1) MA39374A1 (uk)
MX (1) MX2016013425A (uk)
NZ (1) NZ724644A (uk)
PE (1) PE20161391A1 (uk)
PH (1) PH12016501951A1 (uk)
PL (1) PL3129392T3 (uk)
PT (1) PT3129392T (uk)
RS (1) RS60959B1 (uk)
SG (2) SG11201608041QA (uk)
SI (1) SI3129392T1 (uk)
TW (1) TWI659964B (uk)
UA (1) UA120927C2 (uk)
UY (1) UY36070A (uk)
WO (1) WO2015157483A1 (uk)
ZA (1) ZA201606748B (uk)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015157483A1 (en) 2014-04-11 2015-10-15 Bristol-Myers Squibb Company Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
EP3377177A2 (en) * 2015-11-20 2018-09-26 VIIV Healthcare UK(No.4) Limited Hiv maturation inhibitor formulations
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20190183901A1 (en) * 2016-08-31 2019-06-20 Viiv Healthcare Company Combinations and uses and treatments thereof
US20210347813A1 (en) * 2018-04-24 2021-11-11 Viiv Healthcare Uk (No. 5) Limited Compounds with hiv maturation inhibitory activity
PT3894424T (pt) * 2018-12-10 2023-02-28 Viiv Healthcare Uk No 4 Ltd Sal mesilato de um composto de amino-lupano com atividade inibidora da maturação do vih
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
CN110981765A (zh) * 2019-11-07 2020-04-10 肇庆巨元生化有限公司 一种25-羟基维生素d3中间体的制备方法
UY38982A (es) * 2019-12-09 2021-06-30 Viiv Healthcare Co Composiciones farmacéuticas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906661A (en) 1981-11-12 1990-03-06 E. I. Du Pont De Nemours And Company Esters of aryloxypropanolamine derivatives
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
RU2387665C2 (ru) 2004-03-17 2010-04-27 Панакос Фармасьютикалз, Инк. Фармацевтические соли 3-о-(3', 3'-диметилсукцинил)бетулиновой кислоты
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
EP2178376A4 (en) * 2007-08-03 2011-12-14 Advanced Life Sciences Inc LUPANIC TRITERPENOIDS MODIFIED IN 30-POSITION AND ITS ANALOG
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
ES2548905T3 (es) 2010-06-04 2015-10-21 Bristol-Myers Squibb Company Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH
WO2011153315A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
EP2670764B1 (en) 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
JP6001560B2 (ja) 2011-01-31 2016-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2015157483A1 (en) 2014-04-11 2015-10-15 Bristol-Myers Squibb Company Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent

Also Published As

Publication number Publication date
CR20160472A (es) 2017-03-10
IL248053A0 (en) 2016-11-30
US10245275B2 (en) 2019-04-02
EA201691760A1 (ru) 2017-02-28
MA39374A1 (fr) 2018-06-29
CA2944778C (en) 2022-06-14
US9527882B2 (en) 2016-12-27
US20190151336A1 (en) 2019-05-23
BR112016023414A2 (uk) 2017-08-15
US11464790B2 (en) 2022-10-11
DOP2016000277A (es) 2017-02-28
LT3129392T (lt) 2020-11-10
JP2017510659A (ja) 2017-04-13
JP6568202B2 (ja) 2019-08-28
US20150291655A1 (en) 2015-10-15
PH12016501951B1 (en) 2017-01-09
MX2016013425A (es) 2017-05-02
PT3129392T (pt) 2020-10-30
PE20161391A1 (es) 2017-01-10
DK3129392T3 (da) 2020-10-19
EP3129392B1 (en) 2020-08-05
HRP20201645T1 (hr) 2020-12-25
NZ724644A (en) 2023-07-28
AU2015243500B2 (en) 2017-03-30
BR112016023414B1 (pt) 2022-09-13
US20200360404A1 (en) 2020-11-19
TWI659964B (zh) 2019-05-21
HUE051719T2 (hu) 2021-03-29
AR101077A1 (es) 2016-11-23
EP3750910A1 (en) 2020-12-16
CN106604909A (zh) 2017-04-26
PL3129392T3 (pl) 2021-04-06
CA2944778A1 (en) 2015-10-15
TW201623324A (zh) 2016-07-01
ES2828705T3 (es) 2021-05-27
KR102411082B1 (ko) 2022-06-17
WO2015157483A1 (en) 2015-10-15
CY1123742T1 (el) 2022-03-24
IL248053B (en) 2020-04-30
EP3129392A1 (en) 2017-02-15
UY36070A (es) 2015-10-30
SG11201608041QA (en) 2016-10-28
CL2016002528A1 (es) 2017-06-23
RS60959B1 (sr) 2020-11-30
US20170340650A1 (en) 2017-11-30
EA030178B1 (ru) 2018-06-29
ZA201606748B (en) 2018-05-30
CN106604909B (zh) 2019-02-15
US10780102B2 (en) 2020-09-22
US20170056420A1 (en) 2017-03-02
SG10201709017PA (en) 2017-11-29
AU2015243500A1 (en) 2016-10-27
SI3129392T1 (sl) 2020-11-30
KR20160147809A (ko) 2016-12-23
PH12016501951A1 (en) 2017-01-09

Similar Documents

Publication Publication Date Title
UA120927C2 (uk) Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл
PH12014501816A1 (en) C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity
MX2015010003A (es) Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
PH12018500061A1 (en) Oxysterols and methods of use thereof
GEP20197003B (en) Aminopyrimidinyl compounds as jak inhibitors
PH12017501255A1 (en) Tricyclic spiro compound
PH12016501963B1 (en) Macrocyclic pyrimidine derivatives
MX2014013089A (es) Aminas biciclicas c-17 de triterpenoides con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
PH12016501962A1 (en) Macrocyclic pyridine derivatives
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
MX2020005079A (es) Derivados de aminotiazol utiles como agentes antiviricos.
MX2018009514A (es) Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1.
TN2016000490A1 (en) Naphthyridinedione derivatives.
WO2015198263A3 (en) Novel betulinic proline substituted derivatives as hiv inhibitors
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
PH12016501215A1 (en) Azaindole derivative
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors